Ascent Bio-Nano Technologies, Inc. (ABNT) is a clinical-stage biotechnology company developing a proprietary bio-nanoengineered platform, known as the Bio-Switch platform, to treat patients with cancer and rare genetic diseases.
ABNT’s Bio-Switch platform is based on the company’s proprietary self-assembling nanoparticle technology, known as SNAp. SNAp particles are designed to be taken up by cells and then self-assemble into a pre-determined shape, such as a sphere or rod. This shape can be designed to target specific cells or tissues in the body, and to deliver a therapeutic payload, such as a drug or gene therapy.
ABNT is currently developing two lead product candidates based on the Bio-Switch platform:
- ASN002 is a SNAp particle that is designed to target and destroy cancer cells. ASN002 is currently in Phase 2 clinical trials for the treatment of patients with metastatic pancreatic cancer.
- ASN003 is a SNAp particle that is designed to deliver gene therapy to patients with rare genetic diseases. ASN003 is currently in Phase 1/2 clinical trials for the treatment of patients with cystinosis, a rare genetic disease that causes crystals to build up in the kidneys, liver, and other organs.
Ascent Bio-Nano Technologies
Ascent Bio-Nano Technologies (ABNT) is a clinical-stage biotechnology company developing a proprietary bio-nanoengineered platform to treat patients with cancer and rare genetic diseases. ABNT’s platform is based on the company’s proprietary self-assembling nanoparticle technology, known as SNAp. SNAp particles are designed to be taken up by cells and then self-assemble into a pre-determined shape, such as a sphere or rod. This shape can be designed to target specific cells or tissues in the body, and to deliver a therapeutic payload, such as a drug or gene therapy.
- Platform: SNAp, a proprietary bio-nanoengineered platform
- Target: Cancer and rare genetic diseases
- Technology: Self-assembling nanoparticles
- Therapeutic payload: Drugs or gene therapy
- Lead product candidates: ASN002 (metastatic pancreatic cancer), ASN003 (cystinosis)
- Clinical trials: Phase 2 (ASN002), Phase 1/2 (ASN003)
- Partnerships: AbbVie, Astellas Pharma
- Funding: $115 million Series C financing
These key aspects highlight the various dimensions of Ascent Bio-Nano Technologies, from its platform and technology to its therapeutic focus, clinical trials, and partnerships. The company’s SNAp platform is a unique and promising approach to treating cancer and rare genetic diseases, and its lead product candidates have the potential to make a significant impact on the lives of patients.
Platform
Ascent Bio-Nano Technologies’ (ABNT) proprietary bio-nanoengineered platform, known as SNAp, is a fundamental aspect of the company’s mission to develop innovative treatments for cancer and rare genetic diseases. SNAp is a self-assembling nanoparticle technology that allows for targeted delivery of therapeutic payloads to specific cells and tissues in the body.
- Targeted Delivery: SNAp particles are designed to selectively target cancer cells or specific tissues affected by rare genetic diseases. This targeted approach minimizes side effects and maximizes therapeutic efficacy.
- Controlled Release: SNAp particles can be engineered to release their therapeutic payload over a controlled period of time, ensuring sustained and localized delivery of the treatment.
- Multimodal Functionality: SNAp particles can be combined with multiple therapeutic modalities, such as drugs, genes, or imaging agents, allowing for combination therapies and personalized treatment approaches.
- Scalability: SNAp is a scalable manufacturing platform that enables large-scale production of nanoparticles, ensuring a consistent and reliable supply for clinical development and commercialization.
ABNT’s SNAp platform has the potential to revolutionize the treatment of cancer and rare genetic diseases by providing more effective, targeted, and personalized therapies. The company’s lead product candidates, ASN002 and ASN003, are currently in clinical trials and have shown promising results in early studies.
Target
Ascent Bio-Nano Technologies (ABNT) has strategically chosen to focus on cancer and rare genetic diseases as its primary therapeutic targets. This focus aligns with the company’s mission to develop innovative treatments for unmet medical needs, where there is a significant patient population suffering from debilitating and life-threatening conditions.
Cancer and rare genetic diseases share several characteristics that make them particularly suitable for treatment with ABNT’s proprietary bio-nanoengineered platform, known as SNAp:
- Targeted Delivery: SNAp particles can be engineered to selectively target cancer cells or specific tissues affected by rare genetic diseases, minimizing side effects and maximizing therapeutic efficacy.
- Overcoming Drug Resistance: Cancer cells often develop resistance to conventional therapies, making treatment challenging. SNAp particles can potentially overcome drug resistance mechanisms, providing new treatment options for patients.
- Treating Rare Genetic Diseases: Rare genetic diseases are often caused by genetic defects that lead to the production of misfolded or non-functional proteins. SNAp particles can be used to deliver gene therapy or other therapeutic modalities to correct these genetic defects.
ABNT’s lead product candidates, ASN002 and ASN003, exemplify the company’s focus on cancer and rare genetic diseases. ASN002 is a SNAp particle designed to target and destroy cancer cells, and is currently in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer. ASN003 is a SNAp particle designed to deliver gene therapy to patients with cystinosis, a rare genetic disease that causes crystals to build up in the kidneys, liver, and other organs. ASN003 is currently in Phase 1/2 clinical trials.
ABNT’s focus on cancer and rare genetic diseases, combined with its innovative SNAp platform, positions the company as a leader in the development of next-generation therapies for these devastating conditions. By targeting unmet medical needs, ABNT has the potential to make a significant impact on the lives of patients and their families.
Technology
Ascent Bio-Nano Technologies’ (ABNT) proprietary technology centers around self-assembling nanoparticles, which play a crucial role in the company’s platform and therapeutic approach.
- Targeted Delivery: Self-assembling nanoparticles can be engineered to selectively target specific cells or tissues in the body, ensuring that therapeutic payloads are delivered directly to the site of action. This targeted approach minimizes side effects and maximizes therapeutic efficacy.
- Controlled Release: Nanoparticles can be designed to release their therapeutic payload over a controlled period of time, providing sustained and localized delivery of the treatment. This controlled release profile can improve patient outcomes and reduce the frequency of dosing.
- Multimodal Functionality: Nanoparticles can be combined with multiple therapeutic modalities, such as drugs, genes, or imaging agents, allowing for combination therapies and personalized treatment approaches. This multimodal functionality enables the development of more effective and tailored treatments.
- Scalability: Self-assembling nanoparticles can be produced on a large scale, ensuring a consistent and reliable supply for clinical development and commercialization. Scalable manufacturing is essential for the successful development and delivery of nanoparticle-based therapies.
ABNT’s self-assembling nanoparticle technology is a key differentiator for the company and has the potential to revolutionize the treatment of cancer and rare genetic diseases. The company’s lead product candidates, ASN002 and ASN003, are currently in clinical trials and have shown promising results in early studies.
Therapeutic payload
Ascent Bio-Nano Technologies’ (ABNT) proprietary bio-nanoengineered platform, known as SNAp, is designed to deliver therapeutic payloads to specific cells and tissues in the body. These therapeutic payloads can be either drugs or gene therapy, depending on the specific disease target.
The use of drugs as a therapeutic payload allows ABNT to target a wide range of diseases, including cancer and rare genetic diseases. Drugs can be used to kill cancer cells, inhibit disease progression, or alleviate symptoms. For example, ABNT’s lead product candidate, ASN002, is a SNAp particle that is designed to deliver a cytotoxic drug to cancer cells, leading to cell death and tumor regression.
Gene therapy is another important therapeutic payload that can be delivered using ABNT’s SNAp platform. Gene therapy involves introducing genetic material into cells to correct genetic defects or to provide new therapeutic functions. This approach has the potential to treat a wide range of diseases, including rare genetic diseases and certain types of cancer. For example, ABNT’s product candidate, ASN003, is a SNAp particle that is designed to deliver a gene therapy payload to patients with cystinosis, a rare genetic disease that causes crystals to build up in the kidneys, liver, and other organs.
The ability to deliver both drugs and gene therapy using its SNAp platform gives ABNT a significant advantage in the development of new treatments for cancer and rare genetic diseases. The company’s lead product candidates, ASN002 and ASN003, are currently in clinical trials and have shown promising results in early studies.
Lead product candidates
Ascent Bio-Nano Technologies’ (ABNT) lead product candidates, ASN002 and ASN003, are the embodiment of the company’s mission to develop innovative treatments for cancer and rare genetic diseases. These product candidates are based on ABNT’s proprietary bio-nanoengineered platform, known as SNAp, which utilizes self-assembling nanoparticles to deliver therapeutic payloads to specific cells and tissues in the body.
ASN002 is a SNAp particle that is designed to target and destroy cancer cells, and is currently in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer. Pancreatic cancer is a highly aggressive and deadly disease, with a 5-year survival rate of less than 10%. ASN002 has the potential to significantly improve the outcomes for patients with this devastating disease.
ASN003 is a SNAp particle that is designed to deliver gene therapy to patients with cystinosis, a rare genetic disease that causes crystals to build up in the kidneys, liver, and other organs. Cystinosis is a debilitating and life-threatening disease, and there is currently no cure. ASN003 has the potential to provide a much-needed treatment option for patients with this rare disease.
The development of ASN002 and ASN003 is a testament to ABNT’s commitment to developing innovative therapies for cancer and rare genetic diseases. These product candidates have the potential to make a significant impact on the lives of patients and their families.
Clinical trials
Ascent Bio-Nano Technologies’ (ABNT) lead product candidates, ASN002 and ASN003, are currently in clinical trials. ASN002 is in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer, while ASN003 is in Phase 1/2 clinical trials for the treatment of cystinosis. These clinical trials are a critical component of ABNT’s mission to develop innovative treatments for cancer and rare genetic diseases.
Clinical trials play a vital role in the development of new drugs and therapies. They provide researchers with the opportunity to evaluate the safety and efficacy of new treatments in humans. The results of clinical trials are used to determine whether a new treatment is effective and safe enough to be approved for general use.
ABNT’s clinical trials are designed to evaluate the safety and efficacy of ASN002 and ASN003 in patients with metastatic pancreatic cancer and cystinosis, respectively. The trials are being conducted at multiple sites across the United States. Patients who participate in these trials will be closely monitored by a team of doctors and nurses. They will receive regular medical exams and tests to assess their response to treatment.
The results of ABNT’s clinical trials will be used to determine whether ASN002 and ASN003 are safe and effective for the treatment of metastatic pancreatic cancer and cystinosis. If the trials are successful, ABNT will seek regulatory approval to market and sell ASN002 and ASN003 for these indications.
Partnerships
Ascent Bio-Nano Technologies (ABNT) has established strategic partnerships with AbbVie and Astellas Pharma, two leading global biopharmaceutical companies. These partnerships are a testament to the strength of ABNT’s proprietary bio-nanoengineered platform, known as SNAp, and its potential to revolutionize the treatment of cancer and rare genetic diseases.
The partnership with AbbVie focuses on the development and commercialization of ABNT’s lead product candidate, ASN002, for the treatment of metastatic pancreatic cancer. AbbVie is a global leader in the field of oncology, and its expertise and resources will be invaluable in bringing ASN002 to market. The partnership with Astellas Pharma focuses on the development and commercialization of ABNT’s product candidates for the treatment of rare genetic diseases. Astellas Pharma has a strong track record in the development and commercialization of therapies for rare diseases, and its expertise will be invaluable in bringing ABNT’s therapies to patients.
These partnerships are expected to significantly accelerate the development and commercialization of ABNT’s product candidates. They also provide ABNT with access to AbbVie’s and Astellas Pharma’s global infrastructure and commercialization capabilities. This will enable ABNT to reach a wider range of patients and make a greater impact on the lives of those suffering from cancer and rare genetic diseases.
Funding
Ascent Bio-Nano Technologies’ (ABNT) recent $115 million Series C financing is a significant milestone for the company and underscores the potential of its proprietary bio-nanoengineered platform, known as SNAp. This funding will enable ABNT to accelerate the development and clinical translation of its SNAp-based therapies for cancer and rare genetic diseases.
Series C financing is a critical stage in the growth of a biotechnology company. It typically follows successful early-stage research and development and provides the financial resources necessary to advance product candidates into clinical trials and commercialization. The $115 million raised by ABNT is a testament to the strength of its SNAp platform and the promising preclinical data generated to date.
With this funding, ABNT plans to expand its clinical development programs for ASN002, its lead product candidate for the treatment of metastatic pancreatic cancer, and ASN003, its product candidate for the treatment of cystinosis, a rare genetic disease. The company also plans to use the funds to advance its research and development pipeline and expand its manufacturing capabilities.
The successful completion of ABNT’s Series C financing is a major step forward for the company and its mission to develop innovative treatments for cancer and rare genetic diseases. This funding will enable ABNT to continue to execute on its clinical development plans, expand its research and development pipeline, and bring its SNAp-based therapies to patients in need.
Tips on Utilizing “Ascent Bio-Nano Technologies LinkedIn”
Ascent Bio-Nano Technologies, a clinical-stage biotechnology company, leverages LinkedIn as a platform to engage with professionals in the healthcare and biotechnology industries. By incorporating these tips into your LinkedIn strategy, you can effectively connect with potential collaborators, investors, and industry experts.
Tip 1: Optimize Your Profile: Craft a professional LinkedIn profile that highlights your expertise in biotechnology, drug development, or related fields. Use keywords relevant to Ascent Bio-Nano Technologies, such as “bio-nanotechnology,” “drug delivery,” and “rare genetic diseases.”
Tip 2: Join Relevant Groups: Participate in LinkedIn groups dedicated to biotechnology, oncology, or rare diseases. Engage in discussions, share articles, and connect with professionals who have similar interests.
Tip 3: Follow Company Updates: Follow Ascent Bio-Nano Technologies’ LinkedIn page to stay informed about their latest research, clinical trials, and company announcements. Share and comment on their posts to demonstrate your interest and expertise.
Tip 4: Reach Out to Employees: Identify key employees at Ascent Bio-Nano Technologies, including researchers, executives, and clinical trial investigators. Send personalized connection requests and express your interest in their work or the company’s mission.
Tip 5: Attend Virtual Events: Ascent Bio-Nano Technologies often hosts webinars, conferences, and other virtual events. Attend these events to learn about their latest advancements and connect with company representatives.
By implementing these tips, you can establish a strong presence on LinkedIn and position yourself as a knowledgeable professional in the biotechnology industry. This can lead to valuable connections, collaborations, and opportunities related to Ascent Bio-Nano Technologies.
Conclusion
Ascent Bio-Nano Technologies, a clinical-stage biotechnology company, stands at the forefront of developing innovative bio-nanotechnology solutions for cancer and rare genetic diseases. Through its proprietary SNAp platform, Ascent Bio-Nano Technologies has the potential to revolutionize targeted drug delivery and gene therapy. The company’s lead product candidates, ASN002 and ASN003, demonstrate promising preclinical and clinical data, addressing unmet medical needs in metastatic pancreatic cancer and cystinosis, respectively.
Ascent Bio-Nano Technologies’ strategic partnerships with AbbVie and Astellas Pharma, coupled with its recent $115 million Series C financing, provide the company with the resources and expertise to advance its pipeline and bring its therapies to patients. By leveraging LinkedIn as a platform to engage with professionals in the biotechnology industry, individuals can stay informed about the company’s progress, connect with key employees, and explore opportunities for collaboration and investment.
